ChemoMetec Overview
- Year Founded
-
1997
- Status
-
Public
- Employees
-
174
- Stock Symbol
-
CHEMM
- Investments
-
1
- Share Price
-
$101.76
- (As of Friday Closing)
ChemoMetec General Information
Description
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells, as well as image analysis. The company operates in the following categories: instruments, consumables (which derive maximum revenue), services, and others. Geographically, it derives maximum revenue from the United States and Canada, followed by Europe and the Rest of the world.
Contact Information
Website
www.chemometec.comCorporate Office
- Gydevang 43
- 3450 Allerod
- Denmark
Corporate Office
- Gydevang 43
- 3450 Allerod
- Denmark
ChemoMetec Stock Performance
As of 13-Nov-2026, ChemoMetec’s stock price is $101.76. Its current market cap is $1.75B with 17.2M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $101.76 | $101.66 | $36.53 - $122.36 | $1.75B | 17.2M | 68.5K | $1.81 |
ChemoMetec Financials Summary
As of 30-Jun-2026, ChemoMetec has a trailing 12-month revenue of $79.8M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2026 30-Jun-2026 | FY 2025 30-Jun-2025 | FY 2024 30-Jun-2024 |
|---|---|---|---|---|
| EV | 921,781 | 921,781 | 1,558,366 | 728,470 |
| Revenue | 79,798 | 79,798 | 72,185 | 59,163 |
| EBITDA | 44,538 | 44,538 | 35,132 | 26,966 |
| Net Income | 31,515 | 31,515 | 25,446 | 19,768 |
| Total Assets | 131,521 | 131,521 | 131,943 | 97,138 |
| Total Debt | 701 | 701 | 1,007 | 596 |
ChemoMetec Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ChemoMetec Comparisons
Industry
Financing
Details
ChemoMetec Competitors (25)
One of ChemoMetec’s 25 competitors is Cytek Biosciences, a Formerly VC-backed company based in Fremont, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cytek Biosciences | Formerly VC-backed | Fremont, CA | ||||
| Meridian Bioscience | Private Equity-Backed | Cincinnati, OH | ||||
| 10x Genomics | Formerly VC-backed | Pleasanton, CA | ||||
| Aligned Genetics | Formerly VC-backed | Gunpo, South Korea | ||||
| Bio-Techne | Corporation | Minneapolis, MN |
ChemoMetec Patents
ChemoMetec Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4416567-A1 | Method for monitoring a liquid culture flow | Active | 14-Oct-2021 | ||
| EP-4416567-B1 | Method for monitoring a liquid culture flow | Active | 14-Oct-2021 | ||
| EP-4416567-C0 | Method for monitoring a liquid culture flow | Active | 14-Oct-2021 | ||
| US-20240368523-A1 | Method for monitoring a liquid culture flow | Pending | 14-Oct-2021 | ||
| EP-4305197-A1 | Assessment of biological particles immobilized in a hydrogel | Pending | 11-Mar-2021 | C12Q1/6846 |
ChemoMetec Signals
ChemoMetec Acquisitions (1)
ChemoMetec’s most recent deal was a Merger/Acquisition with Ovizio for . The deal was made on 22-Oct-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Ovizio | 22-Oct-2024 | Merger/Acquisition | Other Devices and Supplies |
ChemoMetec ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
20.35 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Laboratory Equipment and Services
Subindustry
of 67
Rank
Percentile
ChemoMetec Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Ovizio | La Hulpe, Belgium | 2009 |
ChemoMetec FAQs
-
When was ChemoMetec founded?
ChemoMetec was founded in 1997.
-
Where is ChemoMetec headquartered?
ChemoMetec is headquartered in Allerod, Denmark.
-
What is the size of ChemoMetec?
ChemoMetec has 174 total employees.
-
What industry is ChemoMetec in?
ChemoMetec’s primary industry is Monitoring Equipment.
-
Is ChemoMetec a private or public company?
ChemoMetec is a Public company.
-
What is ChemoMetec’s stock symbol?
The ticker symbol for ChemoMetec is CHEMM.
-
What is the current stock price of ChemoMetec?
As of 13-Nov-2026 the stock price of ChemoMetec is $101.76.
-
What is the current market cap of ChemoMetec?
The current market capitalization of ChemoMetec is $1.75B.
-
What is ChemoMetec’s current revenue?
The trailing twelve month revenue for ChemoMetec is $79.8M.
-
Who are ChemoMetec’s competitors?
Cytek Biosciences, Meridian Bioscience, 10x Genomics, Aligned Genetics, and Bio-Techne are some of the 25 competitors of ChemoMetec.
-
What is ChemoMetec’s annual earnings per share (EPS)?
ChemoMetec’s EPS for 12 months was $1.81.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process